A new AI model, Clairity Breast, predicts five-year breast cancer risk from mammograms better than traditional breast density assessments. This FDA-authorized, image-only AI evaluates subtle breast tissue changes unrecognizable by the human eye, improving risk stratification.
Breast density alone is a weak predictor, covering only a small portion of actual cancer risks among women. The AI model uses deep learning trained on over 400,000 mammograms globally to detect risk patterns more precisely.
How Clairity Breast Works
Clairity Breast was trained on mammograms from women with and without cancer, learning complex tissue patterns linked to future cancer risk. The model produces a risk score categorizing women into average, intermediate, and high-risk groups. Women classified as high-risk by AI were more than four times likelier to develop breast cancer than average-risk women. This surpasses breast density’s more modest risk differentiation and supports a more personalized approach to screening and prevention.
Implications for Screening and Early Detection
Current screening guidelines generally recommend mammograms starting at age 40 for average-risk women. However, breast cancer incidence is rising fastest in women under 40, raising concerns about early detection.
The AI model’s ability to identify high-risk women, even those under 30, could enable earlier and more tailored screening pathways. This proactive risk assessment may significantly improve outcomes by catching cancers earlier in vulnerable populations.
Addressing Limitations of Breast Density Legislation
Breast density notification laws in many states require informing women if their mammograms show dense breasts, which is linked to an increased risk. But dense breast tissue alone is insufficient for accurate risk prediction.
Expert researchers recommend combining breast density information with AI-derived risk scores to provide women clearer, actionable insights. This dual approach empowers women and clinicians to pursue appropriate screening and risk-reducing strategies.
This breakthrough AI model introduces a paradigm shift in breast cancer risk assessment, offering hope for more effective early detection and personalized screening. It complements traditional factors and could transform breast cancer prevention strategies worldwide.
Frequently Asked Questions (FAQs)
Q1: What makes Clairity Breast different from traditional risk assessments?
It uses AI to analyze mammogram images alone, detecting complex tissue changes invisible to radiologists, providing stronger risk predictions than breast density or family history alone.
Q2: How accurate is the AI model?
Validated on over 120,000 mammograms across diverse populations, it demonstrated high accuracy (AUC of 0.72) with well-calibrated risk estimates closely aligning with actual cancer outcomes.
Q3: Can AI predict breast cancer risk for younger women too?
Yes, Clairity Breast identifies high-risk women under 40 and even in their 30s, enabling the possibility of earlier, personalized screening protocols for those at greater risk.
Q4: Is breast density still important if AI risk prediction is used?
Yes, breast density remains relevant but should be combined with AI risk scores to provide a fuller, more precise picture of a woman’s breast cancer risk.
Q5: How might this AI impact clinical practice?
The AI risk model can guide personalized decisions on screening intervals, supplemental imaging (like MRI), and preventive interventions, potentially reducing late-stage cancer diagnoses.